Sotac Pharmaceuticals

Sotac Pharmaceuticals EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Sotac Pharmaceuticals (SOTAC.NS) as of Oct 19, 2026 is 136.49 M INR. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was 82.82 M INR — a change of 64.81% (higher).

EBITDA

136.49 MINR

YoY

64.81%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Sotac Pharmaceuticals is 2025 136.49 M INR. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Sotac Pharmaceuticals was 2024 82.82 M INR. It decreases by 64.81% higher compared to the previous year.

The Sotac Pharmaceuticals EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2020
18.62 M INR
Jan 1, 2021
14.55 M INR
Jan 1, 2022
79.71 M INR
Jan 1, 2023
82.08 M INR
Jan 1, 2024
82.82 M INR
Jan 1, 2025
136.49 M INR
The Sotac Pharmaceuticals EBITDA history
YEAREBITDAYoY
136.49 MINR+64.81%
82.82 MINR+0.90%
82.08 MINR+2.97%
79.71 MINR+447.96%
14.55 MINR-21.87%
18.62 MINR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Sotac Pharmaceuticals Stock analysis

What does Sotac Pharmaceuticals do? Sotac Pharmaceuticals Ltd., headquartered in Ahmedabad, Gujarat, operates in the Health Care sector, specializing in pharmaceutical manufacturing. The company develops and manufactures products such as Non Beta-Lactam tablets, capsules, syrups, and external preparations on a contract basis for various marketers. Its therapeutic portfolio covers Anti-Diabetic, Anti-Psychotic, Vitamins, Minerals, Anti-Cold, Anti-Allergic, Derma Products, and a wide range of antibiotics including Non-IP-Lactams and Cephalosporin. Listed on 13 April 2023, Sotac employs 89 people and has subsidiaries including SOTAC Healthcare, SOTAC Research, and SOTAC Lifescience. Sotac Pharmaceuticals is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Sotac Pharmaceuticals stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Sotac Pharmaceuticals is 136.49 M INR in 2025.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Sotac Pharmaceuticals changed from 82.82 M INR to 136.49 M INR, representing a 64.81% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Sotac Pharmaceuticals since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s INR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Sotac Pharmaceuticals historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Income Statement — Sotac Pharmaceuticals

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — Sotac Pharmaceuticals